20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for improved solubility of APIs and extended release. Validated as an eye drop, we have successful pre-clinical studies in glaucoma, dry eye and uveitis.
20/20 OptimEyes Technologies is seeking partners to further develop ophthalmic assets or those with novel or repurposed APIs for co-development opportunities in humans and companion animals. The company is also looking for partners with assets targeting other mucosal areas (nasal, optic, buccal, vaginal or GI).
Intellectual Property
Fundraising
Are you developing and/or redesigning new green products, services, processes, and technologies that reduce environmental impact?
The i.d.e.a.™ Fund program focuses on supporting a more sustainable economy while fostering an inclusive and equitable growth in southern Ontario. Find out if you’re eligible to access up to $20,000 in matching seed funding and 30 hours of expert mentorship.
Applications are open from June 16 to July 7, 2025.
